Last year, first-of-a-kind drug approvals by the FDA reached their highest level in 19 years. The annual total of first-of-a-kind drugs increased to this level because of the drug industry’s focus on drugs designed to treat rare and hard-to-treat diseases. In 2015, the Food and Drug Administration (FDA) approved 45 drugs with never-before-sold ingredients.
The FDA’s approvals are considered innovative in the treatment of rare and hard-to-treat diseases. This should be considered big news for the pharmaceutical companies as well as patients. However, specialty drugs on the market are accompanied by controversy over the enormous increase in drug costs to patients.
In fact, one of the most expensive drugs of the year was produced by Vertex Pharmaceuticals. The drug, Orkambi, is appropriate for treatment of cystic fibrosis. It is one of the most expensive drugs on the market and sells for $259,000 per year. The drug has been proven to iincrease lung function in patients with the deadly inherited lung disease. Cystic fibrosis is a disease that causes the buildup of sticky mucus to develop throughout the body.